Trade Biora Therapeutics Inc. - BIOR CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0532 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024929% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002707% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.2984 |
Open | 3.2984 |
1-Year Change | 76.27% |
Day's Range | 2.7984 - 3.2984 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 4, 2024 | 2.8984 | -0.4000 | -12.13% | 3.2984 | 3.3084 | 2.7684 |
Nov 1, 2024 | 3.2984 | -0.0100 | -0.30% | 3.3084 | 3.4284 | 3.2984 |
Oct 31, 2024 | 3.3884 | -0.0600 | -1.74% | 3.4484 | 3.4784 | 3.3084 |
Oct 30, 2024 | 3.4484 | -0.1000 | -2.82% | 3.5484 | 3.5484 | 3.3484 |
Oct 29, 2024 | 3.4784 | -0.2800 | -7.45% | 3.7584 | 3.8184 | 3.3984 |
Oct 28, 2024 | 4.3584 | 0.0900 | 2.11% | 4.2684 | 4.3984 | 3.9984 |
Oct 25, 2024 | 3.8984 | 0.4300 | 12.40% | 3.4684 | 4.1984 | 3.4684 |
Oct 24, 2024 | 3.4984 | 0.0000 | 0.00% | 3.4984 | 3.5984 | 3.2984 |
Oct 23, 2024 | 3.7484 | -0.6000 | -13.80% | 4.3484 | 4.3484 | 3.6384 |
Oct 22, 2024 | 4.4684 | 0.0200 | 0.45% | 4.4484 | 4.6284 | 4.3784 |
Oct 21, 2024 | 4.4584 | 0.1500 | 3.48% | 4.3084 | 4.5884 | 4.0584 |
Oct 18, 2024 | 4.2584 | -1.2616 | -22.86% | 5.5200 | 5.5200 | 4.0884 |
Oct 17, 2024 | 0.5520 | -0.0125 | -2.21% | 0.5645 | 0.5724 | 0.5291 |
Oct 16, 2024 | 0.5875 | 0.0356 | 6.45% | 0.5519 | 0.5909 | 0.5334 |
Oct 15, 2024 | 0.5430 | 0.0170 | 3.23% | 0.5260 | 0.5524 | 0.5211 |
Oct 14, 2024 | 0.5229 | -0.0055 | -1.04% | 0.5284 | 0.5435 | 0.5184 |
Oct 11, 2024 | 0.5490 | 0.0606 | 12.41% | 0.4884 | 0.5536 | 0.4884 |
Oct 10, 2024 | 0.5445 | 0.0161 | 3.05% | 0.5284 | 0.5484 | 0.5184 |
Oct 9, 2024 | 0.5287 | 0.0003 | 0.06% | 0.5284 | 0.5436 | 0.5118 |
Oct 8, 2024 | 0.5391 | -0.0093 | -1.70% | 0.5484 | 0.5485 | 0.5223 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biora Therapeutics Inc. Company profile
Progenity (PROG)/Biora Therapeutics (BIOR) is a biotechnology firm focused on the development of oral biotherapeutics. Founded in 2010, the company creates drug-device combinations that enable new therapeutic delivery methods in two main areas:
Targeted delivery of therapeutics to the site of disease in the gastrointestinal (GI) tract, to improve outcomes for patients with Inflammatory Bowel Disease (IBD)
Systemic biotherapeutic delivery, which is intended to replace injection with needle-free, oral delivery technology
Progenity is also working on diagnostic tools to help characterise the GI tract and diagnose GI diseases such as Small Intestine Bacterial Overgrowth (SIBO). The technologies can pinpoint the location of the disease.
Prior to June 2021, the San Diego, California-based company focused on the prenatal carrier screening and non-invasive prenatal test market. It targeted preconception planning and routine pregnancy management for genetic disease risk assessment.
The company’s operations included anatomic and molecular pathology testing products under an affiliate, Avero Diagnostics.
A former affiliate, Mattison Pathology, a Texas firm trading as Avero Diagnostics, expanded the company’s operations to include anatomic and molecular pathology testing products.
The company also operated a certified laboratory in Michigan that specialised in the molecular testing markets serving women’s health providers in the obstetric, gynaecological, fertility, and maternal foetal medicine speciality areas in the US.
In June 2021, Progenity announced a strategic transformation which included closing the Progenity genetics lab in Ann Arbor, Michigan. It sold the Avero laboratory business in December 2021 as part of the transformation.
On 12 April 2022, Progenity announced it would change its name to Biora Therapeuctics in the second quarter of 2022. The strategy aims to better reflect its focus of developing targeted and systemic oral delivery of biotherapeutics.
The company will also change its stock symbol on the Nasdaq from PROG to BIOR. Progenity went public on 19 June 2020.
Industry: | Bio Therapeutic Drugs |
4330 La Jolla Village Drive
Suite 200
SAN DIEGO
CALIFORNIA 92122
US
News
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024Gold markets to trade
Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.
08:00, 21 October 2024US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com